FamiCord Group
Who we are?
Our history
FamiCord Group cord blood banks have been operating in Europe since 2002. They were grouped in a network in 2006 by Polish Stem Cell Bank (PBKM). Since that time FamiCord Group has been developing internationally and become the largest cord blood bank in Europe and the fifth-largest cord blood bank in the World.
With a wide range of expertise in cell banking & experience in developing our own ATMP cell therapy product, we are offering our diverse cell therapy expertise to assist with contract manufacturing of autologous, allogeneic and viral vector-based products with total flexibility catering to our client needs. Our dedicated core team has experience working with a wide range of technologies working on cell therapies at different scales and stages to cover requirements.
Our facts and figures:
- 13 laboratory facilities: Poland (2), Hungary, Romania, Spain (2), Turkey (2), Switzerland (2), Portugal, Czech Republic, United Kingdom,
- Over 1700 patients treated with ATMP in either hospital exemption or clinical trial settings
- Cooperation with over 1500 hospitals around Europe
- EMA GMP accreditation for ATMP manufacturing across 2 facilities for clinical uses
- FDA approval for supplying stem cells for live-saving transplantations for clinics in the USA.
- 3,000+ sq m of GMP manufacturing capacity
- 30+ dedicated R&D team for analytical and manufacturing process development and transfer
Our facility's flexibility allows us to adapt our facility for client requirements, quality systems in place and EMA regulatory approval allowing us to produce ATMP material for clinical demands offering an end-to-end CDMO service. FamiCord continues to expand its GMP manufacturing capacity to support therapeutic advancement throughout Europe.